VXUS241018C60000
- 4.30
- +0.90+26.47%
Vanguard Total International Stock ETF Newsroom
Teva Launches First U.S. Generic Against Novartis Antidiarrheal Sandostatin LAR
Perspective Draws Buy at Truist on Radiopharma Potential
Vanguard Total International Stock ETF Declares Quarterly Distribution of $0.2723
Novartis Lower as BofA Downgrades on Risks to Valuation
Novartis Licenses Gene Therapy Component From Voyager
VXUS ETF Falls Wednesday
Novartis Expands U.S. Radiopharma Production Amid Rising Competition
Siemens Healthineers Seeks €200M Novartis Deal to Boost Cancer Imaging Business: FT
Novartis Beats Top-line and Bottom-line Estimates; Raises FY24 Core Operating Income Outlook
Novartis, Roche Facing Italy Antitrust Probe Over Lucentis Biosimilar
Travere Gains on Novartis Data for Filspari Rival, Calliditas Buyout
Morgan Stanley Says Global Risk Assets Have 'Good Set-up' in H2 With Cooling Inflation
Kanzhun's Strong Quarter Overshadowed By Broad Sell-Off In Chinese Stocks: Details
HSBC Recommends Where to Invest Globally With Stocks Set to Rise Under Two Scenarios
Bitcoin Stock Canaan Up After Q1 Print, What's Going On?
Radiopharma Stocks Higher as Sector Welcomes the Latest M&A Deal
Earnings Call Summary | Novartis AG(NVS.US) Q1 2024 Earnings Conference
Novartis Beats Top-line and Bottom-line Estimates; Raises FY24 Outlook
FDA Requires Labeling Changes to CAR-T Cell Therapies to Reflect Cancer Risk
TG Therapeutics Wins VA Contract for Briumvi